Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 1/20 | 0.43 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 8/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4852768 | 0.87 | HTT (0.47) | GCKHSPB1TRPA1ARMAP4K4 | |
| SCHEMBL5262766 | 0.79 | HSPB1 (0.44) | HSPB1TRPA1MAP4K4KCNH2MAPK14 | |
| SCHEMBL29909019 | 0.79 | BCHE (0.42) | — | |
| SCHEMBL1991118 | 0.79 | BCHE (0.42) | — | |
| SCHEMBL4849482 | 0.78 | TRPA1 (0.44) | GCKHSPB1TRPA1ARMAP4K4 | |
| SCHEMBL29532068 | 0.71 | KDM4E (0.48) | — | |
| SCHEMBL857818 | 0.71 | KDM4E (0.48) | — | |
| SCHEMBL18646614 | 0.71 | HSPB1 (0.58) | HSPB1ARHTR2ASLC6A4KCNH2 | |
| SCHEMBL27248844 | 0.71 | DHODH (0.47) | SCN4A | |
| Hydrochloric Acid SCHEMBL28031937 | 0.70 | BCHE (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456185-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456185-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456185-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070167471-A1 | Substituted quinazoline compounds useful as p38 kinase inhibitors | DUNN JAMES P | 2007-07-19 | — | — | US | disclosed |
| US-20070167471-A1 | Substituted quinazoline compounds useful as p38 kinase inhibitors | DUNN JAMES P | 2007-07-19 | — | — | US | disclosed |
| US-20070167471-A1 | Substituted quinazoline compounds useful as p38 kinase inhibitors | DUNN JAMES P | 2007-07-19 | — | — | US | disclosed |
| US-7238698-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238698-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238698-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-07-03 | — | — | US | disclosed |
| US-7189731-B2 | Substituted 7-azaquinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189731-B2 | Substituted 7-azaquinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1620408-A2 | QUINAZOLINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004092144-A2 | QUINAZOLINE COMPOUNDS USEFUL AS P38 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209904-A1 | Substituted quinazoline compounds useful as P38 kinase inhibitors | ROCHE PALO ALTO LLC | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167471-A1 | Substituted quinazoline compounds useful as p38 kinase inhibitors | MAPK1, MAPK7, MAPK3 | GCK 651/4885HSPB1 953/4885TRPA1 1846/4885 |
| US-20040209904-A1 | Substituted quinazoline compounds useful as P38 kinase inhibitors | MAPK1, MAPK4, MAPK7 | GCK 578/4885HSPB1 638/4885TRPA1 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.